HUTCHMED Advances Savolitinib with Priority NDA Acceptance in China HUTCHMED, a global biopharma company focused on oncology and immunology, announced that the National Medical Products Administration (NMPA) in China has accepted its new drug application (NDA) for Savolitinib with priority review status. This move follows the company’s recent positive Phase II registration study data in…